Alveolar Soft Part Sarcoma Metastasized to Both the Skull and the Brain

Shin, Tae-Hee; Jung, Young‐Dae; Kim, Oh-Lyong; Kim, Minsu

doi:10.3340/jkns.2012.52.1.55

Cited by 3 publications

(4 citation statements)

References 23 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A malignancy found in younger patients, those diagnosed are mostly below the age of 40 years [ 130 , 131 , 133 , 134 ]. While it metastasizes to lung and bone, unlike other sarcomas, it has a predisposition towards BM with estimates of 15 to 30% in those with stage IV disease [ 1 , 135 ]. On the other hand, ASPS patients have been reported to have greater oncological control with better relapse-free survival [ 1 ]; even though 25% of patients have metastasis at presentation, overall survival is comparatively high at 10–12 years [ 136 , 137 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Brain Metastasis in Bone and Soft Tissue Cancers: A Review of Incidence, Interventions, and Outcomes

Shweikeh

Bukavina

Saeed

et al. 2014

Sarcoma

View full text Add to dashboard Cite

Bone and soft tissue malignancies account for a small portion of brain metastases. In this review, we characterize their incidence, treatments, and prognosis. Most of the data in the literature is based on case reports and small case series. Less than 5% of brain metastases are from bone and soft tissue sarcomas, occurring most commonly in Ewing's sarcoma, malignant fibrous tumors, and osteosarcoma. Mean interval from initial cancer diagnosis to brain metastasis is in the range of 20–30 months, with most being detected before 24 months (osteosarcoma, Ewing sarcoma, chordoma, angiosarcoma, and rhabdomyosarcoma), some at 24–36 months (malignant fibrous tumors, malignant peripheral nerve sheath tumors, and alveolar soft part sarcoma), and a few after 36 months (chondrosarcoma and liposarcoma). Overall mean survival ranges between 7 and 16 months, with the majority surviving < 12 months (Ewing's sarcoma, liposarcoma, malignant fibrous tumors, malignant peripheral nerve sheath tumors, angiosarcoma and chordomas). Management is heterogeneous involving surgery, radiosurgery, radiotherapy, and chemotherapy. While a survival advantage may exist for those given aggressive treatment involving surgical resection, such patients tended to have a favorable preoperative performance status and minimal systemic disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Neurosurgical resection can be favorable and may increase long-term survival [ 1 , 132 , 133 , 135 ]. A surgical advantage may exist with ASPS when compared to other sarcomas.…”

Section: Resultsmentioning

confidence: 99%

Brain Metastasis in Bone and Soft Tissue Cancers: A Review of Incidence, Interventions, and Outcomes

Shweikeh

Bukavina

Saeed

et al. 2014

Sarcoma

View full text Add to dashboard Cite

show abstract

“…Our study identified alveolar soft-tissue sarcoma as the most common histological subtype of STS in patients with BM, followed by angiosarcoma and leiomyosarcoma. Alveolar soft part sarcomas have shown predisposition toward the brain with estimates of 15% to 30% in patients with stage IV disease, 6 , 17 but with a longer mean survival when compared with the overall survival (32.3 versus 10.22 months) (Table 2 ). Unfortunately, most of the evidence concerning this subtype of STS derives from case reports and small series.…”

Section: Discussionmentioning

confidence: 99%

Brain Metastases in Patients With Soft-Tissue Sarcomas: Management and Survival—A SEER Population-Based Cohort Study

Gonzalez¹,

Bryce-Alberti²,

León-Abarca³

et al. 2021

JAAOS Glob Res Rev

View full text Add to dashboard Cite

Introduction: Brain metastases (BM) in soft-tissue sarcomas (STS) is associated with poor prognosis. This large population analysis presents (1) demographic and clinical variables of these patients, (2) potential risk factors, (3) impact of BM on overall survival, and (4) treatment strategies. Methods: Patients with STS and BM were identified from the Surveillance, Epidemiology, and End Results database. Demographic and clinical variables, as well as treatment modalities, were analyzed. Overall 5-year survival was calculated using the Kaplan-Meier method, and the survival difference was assessed using the log-rank test. A multivariate analysis was performed using the Cox proportional hazard regression to determine the risk factors. Results: Twenty-two patients (22/8,433) with STS presented BM at diagnosis. A multivariate analysis showed that women and American Indians/Alaska Natives had a greater risk of presenting BM. The most common histological subtype to metastasize to the brain was alveolar soft part sarcoma (4/22). In 54.5% of patients with BM, the tumor had also metastasized to the lung, although having synchronous bone, liver, and lung metastases showed the greatest increase in risk for presenting BM (odd ratio [OR] = 1,857.7, confidence interval [CI] 95%, 88.4 to 3,9046.6, P < 0.0001). Individually, bone metastasis increased the risk of presenting BM the most (OR = 205.0, CI 95%, 30.5 to 1,379.6, P < 0.0001). The mean survival of patients with BM was 10.22 months. The standard treatment approach included surgery, radiation therapy, and chemotherapy. Conclusion: BM in patients with STS represents an infrequent but lethal event. Women and American Indians/Alaska Natives are at a higher risk of presenting BM, as well as patients with synchronous metastases. Patients are mainly managed with systemic therapy.

show abstract

“…In young adults, the neoplasm often develops in the extremities. The head and neck region is more common for children and adolescents [2][3][4], but has also been described in adults [5]. ASPS appearing in the perianal/perineal region is very unusual and is often identified as a mass in clinical examination [6,7].…”

Section: Introductionmentioning

confidence: 99%